% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Loch:267553,
      author       = {F. N. Loch and C. Kamphues and K. Beyer and C. Schineis and
                      W. Rayya and J. C. Lauscher and D. Horst and M.-P.
                      Dragomir$^*$ and S. Schallenberg},
      title        = {{T}he {I}mmune {C}heckpoint {L}andscape in {T}umor {C}ells
                      of {P}ancreatic {D}uctal {A}denocarcinoma.},
      journal      = {International journal of molecular sciences},
      volume       = {24},
      number       = {3},
      issn         = {1422-0067},
      address      = {Basel},
      publisher    = {Molecular Diversity Preservation International},
      reportid     = {DKFZ-2023-00331},
      pages        = {2160},
      year         = {2023},
      abstract     = {Immune checkpoint therapy (ICT) has shown promising
                      potential in the treatment of multiple solid tumors.
                      However, the role of ICT in pancreatic ductal adenocarcinoma
                      (PDAC) remains limited. Patterns of immune checkpoints (ICs)
                      in PDAC represent the basis for establishing a potent ICT.
                      The aim of this study is to create a profile of IC
                      expression and its prognostic relevance in cancer cells of
                      PDAC. Therefore, tumor cells from peripheral and central
                      tissue microarray (TMA) spots from histologically confirmed
                      PDAC of 68 patients after tumor resection were investigated
                      in terms of expressions of TIM3, IDO, B7H4, LAG3, VISTA, and
                      PD-L1 using immunohistochemistry. The presence of the
                      respective ICs was compared to overall survival (OS). The
                      presence of VISTA and PD-L1 significantly correlates with
                      shorter OS (median OS: 22 months vs. 7 months and 22 months
                      vs. 11 months, respectively, p < 0.05). For the presence of
                      TIM3, IDO, B7H4, and LAG3, no difference in OS was observed
                      (p > 0.05). The analysis of OS of combined subgroups for
                      VISTA and PD-L1 (VISTA and PD-L1 neg., VISTA pos. and PD-L1
                      neg., VISTA neg. and PD-L1 pos., and VISTA and PD-L1 pos.)
                      yielded overall statistical significance difference (p =
                      0.02). These results suggest that the presence of VISTA and
                      PD-L1 is of prognostic relevance and potentially qualifies
                      them as targets for ICT.},
      keywords     = {immune checkpoint inhibitors (Other) / immune checkpoint
                      treatment (Other) / immune checkpoints (Other) / pancreatic
                      ductal adenocarcinoma (Other) / survival (Other)},
      cin          = {BE01},
      ddc          = {540},
      cid          = {I:(DE-He78)BE01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:36768480},
      doi          = {10.3390/ijms24032160},
      url          = {https://inrepo02.dkfz.de/record/267553},
}